i do think that the main game in the first half of c22 is to get a sniff around the cns candidate. Even if it is named that would be a significant help ( and what it is targeting). This potentially results in some kind of platform deal or drug and platform deal as we only have enough cash for RP11 thru to market. The second optic candidate is a silmilar story and while it is more advanced i think the cns target sounds sexier. If we can get one company ( huge) to take an interest in more than one drug then we are set….
Ann: Quarterly Activities and Appendix 4C Cash Flow Report, page-10
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.0¢ |
Change
0.005(2.70%) |
Mkt cap ! $886.5M | |||
| Open | High | Low | Value | Volume |
| 19.0¢ | 19.0¢ | 18.0¢ | $125.5K | 667.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 11936 | 18.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.0¢ | 40292 | 1 |
View Market Depth
| Last trade - 16.10pm 01/11/2024 (20 minute delay) ? |
| PYC (ASX) Chart |